IMMU - イミュノメディクス (Immunomedics Inc.) イミュノメディクス

 IMMUのチャート


 IMMUの企業情報

symbol IMMU
会社名 Immunomedics Inc. (イミュノメディクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イミュノメディックス(Immunomedics Inc.)は癌、自己免疫疾患及び他の重篤な疾患の治療用のモノクローナル抗体ベースの製品の開発に集中するバイオ医薬品会社である。同社は地理的な事業は米国と欧州を含む。同社の技術は、非標識または裸の形で単独で、または放射性同位体、化学療法剤、サイトカインまたは毒素と結合して使用できるヒト化抗体を作製することを可能にする。同社は8つの臨床段階の製品候補のパイプラインを有する。その治験薬のポートフォリオには、化学療法薬のペイロードを腫瘍に直接送達するように設計された抗体 - 薬物コンジュゲート(ADC)が含まれ、これらの化学療法薬の従来の投与で見出される全体的な毒性効果を管理する。そのADCは、第II相試験中のsacituzumab govitecan(IMMU-132)およびlabetuzumab govitecan(IMMU-130)である。   イミュノメディクスは、米国のバイオ製薬会社。癌、自己免疫疾患の治療のために、モノクロ―ナル抗体をベ―スとした製品を開発。製品候補には、CD22を標的とするヒト化抗体エプラツズマブがある。CD22は、Bリンパ球の表面に見出される抗原、白血球の種類である。また、膵臓癌患者の治療に、イットリウム-90標識クリバツズマブ・テトラキセタンを開発。   Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
本社所在地 300 The American Road Morris Plains NJ 07950 USA
代表者氏名 Behzad Aghazadeh Behzad Aghazadeh
代表者役職名 Independent Chairman of the Board
電話番号 +1 973-605-8200
設立年月日 30133
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 185人
url www.immunomedics.com
nasdaq_url https://www.nasdaq.com/symbol/immu
adr_tso
EBITDA EBITDA(百万ドル) -139.75000
終値(lastsale) 20.01
時価総額(marketcap) 3738508540.11
時価総額 時価総額(百万ドル) 4474.626
売上高 売上高(百万ドル) 2.15600
企業価値(EV) 企業価値(EV)(百万ドル) 3855.58701
当期純利益 当期純利益(百万ドル) -273.83690
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Immunomedics Inc. revenues decreased 30% to $2.2M. Net loss increased 79% to $273.8M. Revenues reflect Europe segment decrease of 39% to $1.5M. Higher net loss reflects Research and development - Balancing val increase of 97% to $96.9M (expense) Changes in fair market value of warrant increase of 78% to $108.6M (expense).

 IMMUのテクニカル分析


 IMMUのニュース

   The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO  2020/09/02 11:25:11 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Entera Bio Ltd (NASDAQ: ENTX ) Freeline Therapeutics Holdings PLC (NASDAQ: FRLN ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Immatics NV (NASDAQ: IMTX ) NanoVibronix Inc (NASDAQ: NAOV ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Predictive Oncology Inc (NASDAQ: POAI ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Stocks In Focus Mesoblast Gets Ethics Approval For Using Stem Cell Therapy In COVID-19 Patients In Australia Mesoblast (NASDAQ: MESO ) said it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.
   Fund manager Tom O'Halloran quadrupled investors' money in 9 years by betting on super high-growth companies. He explained his approach, and why new technologies could make the next decade for markets even better than the 2010s.  2020/08/04 12:03:00 Business Insider
Thomas O'Halloran manages the Lord Abbett Growth Leaders Fund , which has more than quadrupled investors' money in nine years by investing in high-growth tech, consumer, and healthcare stocks. He's even more optimistic about the coming decade, reasoning that the combination of the "technology revolution" and low interest rates should keep a secular bull market going through 2030. He also says there's little reason to worry about the market dominance of Big Tech because companies like Microsoft and Amazon are innovating in ways that help other companies succeed. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . A lot of experts go back and forth between praising Big Tech and worrying that it is dangerously dominant — but Thomas O'Halloran is consistent in thinking the companies deserve their success. "These companies are the greatest companies the planet has ever seen," he said of Apple , Microsoft , Amazon , Alphabet , and Facebook . "I don't worry about it at all, the concentration.
   Immunomedics Expands Partnership With Roche on Lung Cancer Treatments | MarketScreener  2020/07/13 21:08:01 MarketScreener
By Kimberly Chin Immunomedics Inc. said it has extended its partnership with Roche Holding Ltd. on clinical trials of their combined treatments for patients with metastatic urothelial cancer… | July 13, 2020
   Immunomedics expands Roche partnership with two new trials (NASDAQ:IMMU)  2020/07/13 20:19:42 Seeking Alpha
Immunomedics (NASDAQ:IMMU) will extend its clinical collaboration with Roche (OTCQX:RHHBY) with two new clinical trials evaluating the combination of anti-
   Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers  2020/07/13 20:00:00 GlobeNewswire
Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in…
   Immunomedics Expands Partnership With Roche on Lung Cancer Treatments | MarketScreener  2020/07/13 21:08:01 MarketScreener
By Kimberly Chin Immunomedics Inc. said it has extended its partnership with Roche Holding Ltd. on clinical trials of their combined treatments for patients with metastatic urothelial cancer… | July 13, 2020
   Immunomedics expands Roche partnership with two new trials (NASDAQ:IMMU)  2020/07/13 20:19:42 Seeking Alpha
Immunomedics (NASDAQ:IMMU) will extend its clinical collaboration with Roche (OTCQX:RHHBY) with two new clinical trials evaluating the combination of anti-
   Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers  2020/07/13 20:00:00 GlobeNewswire
Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in…
   Shares of Immunomedics jump on positive confirmatory data for its breast-cancer drug  2020/07/06 14:54:10 MarketWatch
Shares of Immunomedics Inc. undefined gained 6.9% in trading on Monday after the drugmaker said a confirmatory Phase 3 clinical trial of its breast-cancer…
   Immunomedics : Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM | MarketScreener  2020/07/06 12:04:08 MarketScreener
Trodelvy significantly improved progression-free survival and overall survival in previously-treated brain metastasis negative patients with advanced mTNBC The… | July 6, 2020
   Is Immunomedics (IMMU) Stock Outpacing Its Medical Peers This Year?  2020/05/18 15:30:14 Zacks Investment Research
Is (IMMU) Outperforming Other Medical Stocks This Year?
   Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus  2020/05/07 15:21:00 Zacks Investment Research
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.
   Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update  2020/05/06 20:00:00 GlobeNewswire
Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following…
   Why Immunomedics (IMMU) Might Surprise This Earnings Season  2020/05/05 14:45:00 Zacks Investment Research
Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Why One Brokerage Isn’t Dialing Verizon Anymore  2020/04/25 00:30:00 Barron's
Also, Wall Street views on Tractor Supply, Canadian Pacific, Snap-on, Extended Stay America, and Immunomedics

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イミュノメディクス IMMU Immunomedics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)